The constituent SH3, SH2, and kinase domains of the Abl kinase regulatory core can adopt an assembled (inactive) or a disassembled (active) conformation. We show that this assembly state strictly correlates with the conformation of the kinase activation loop induced by a total of 14 ATP site ligands, comprising all FDA-approved Bcr-Abl inhibiting drugs. The disassembly of the core by certain ligands can be explained by an induced push on the kinase N-lobe via A-and P-loop towards the SH3 domain. A similar sized P-loop motion is expected during nucleotide binding and release, which would be impeded in the assembled state, in agreement with its strongly reduced kinase activity.
INTRODUCTION
Abelson tyrosine kinase (Abl) plays a crucial role in many cellular processes such as proliferation, division, survival, DNA repair, migration and is an important cancer drug target. [1] [2] [3] The regulatory core of Abl (Figure 1a) consists sequentially of the N-cap, the SH3
and SH2 domains, and the kinase domain (KD) N-and C-lobes, which are separated by the catalytic cleft. 4 This SH3-SH2-KD domain order is conserved among the Abl, Src, Csk, Brk, and Tec non-receptor tyrosine kinase families. Under physiological conditions, Abl is autoinhibited by interactions of the SH3 and SH2 domains with the KD N-and C-lobes, respectively, as well as by the docking of the myristoylated N-terminal glycine-2 (present in the Abl 1b splice variant) into a hydrophobic cavity of the KD C-lobe. 4, 5 This 'assembled' state of the Abl core is observed in crystal structures ( Figure 1a ) 4, 5 as well as in solution 6, 7 in the presence and absence of myristoylation. Similar assembled core structures have so far been observed for the Src 8 and Btk 9 kinases.
Upon activation, the SH3 and SH2 domains disengage from the KD and are able to bind to cellular partners. 2 The high activity of this 'disassembled' state may be explained by the readiness to form such intermolecular interactions, but also intramolecular interactions are involved. In particular, interactions between the Abl SH2 domain and the KD N-lobe have a critical role in leukemogenesis 10 and enhance in vitro kinase activity 11 . Corresponding direct contacts between the SH2 domain and the top of the KD N-lobe have been observed under certain crystal 4, 10, 12 and solution 11, 13 conditions, which may explain the enhanced activity by a modulation of the hinge motion between N-and C-lobes. 14, 15 Abnormal reciprocal translocation between chromosomes 9 and 22 results in the deregulated fusion protein Bcr-Abl and subsequently in chronic myelogenous leukemia (CML). 16 The ATP site inhibitors imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel) represent the front-line therapy against CML. [17] [18] [19] However, spontaneous point mutations render these inhibitors ineffective in a fraction of patients. 18 In particular, the multidrug-resistant "gatekeeper" T334I mutation (Abl 1b numbering) has stimulated the search for new therapeutics. 20, 21 Among those are the ATP site inhibitors ponatinib (Iclusig) 20 and axitinib, 22 as well as the allosteric inhibitor asciminib 23 targeting the myristoyl binding pocket. The presumed mode of action of the latter is a stabilization of the autoinhibited, assembled state. 7, 24 Besides their efficacy against CML, inhibitors of Bcr-Abl are also widely used against Bcr-Abl-expressing subsets of B-cell leukemias, several diseases with Kit and Platelet-derived growth factor receptor (PDGF-R) aberrations, 25 and have promising effects in cell and animal models of Parkinson's disease. 26, 27 Several structural motifs of the Abl KD are conserved in most kinases and crucial for the catalytic function (Figure 1c ): the activation loop (A-loop) with the Asp-Phe-Gly (DFG) motif, the αC helix, and the glycine-rich (phosphate-binding loop) P-loop. 28, 29 The A-loop adopts two major conformations observed in most ligand complexes (Figure 1c,d and Figure   S1 ). 18 For type I inhibitors, the A-loop is in the 'active' (open) conformation positioned towards the αC helix (e.g. in the dasatinib complex) 30 with the aspartate of the DFG oriented 'in' or 'flipped' towards the ATP binding pocket. In contrast, type II inhibitors induce the 'inactive' (closed) conformation of the A-loop, where the entire loop is rotated towards the Ploop (e.g. imatinib complex) and the aspartate oriented 'out' from the ATP pocket. 29 In this conformation, the central part of the A-loop mimics the bound substrate. 31 Both the αC helix position 12,28 and the P-loop conformation 32 vary depending on the A-loop conformation and the interaction with the ligand.
NMR RDC data on the Abl KD prove that in solution the A-loop predominantly (>85 %) adopts the same active conformation in a type I (dasatinib) complex and the same inactive conformation in type II (imatinib and nilotinib) complexes as observed in respective crystal structures. 33 However, backbone 15 N NMR relaxation data also indicate dynamics of the Aloop in the nanosecond and microsecond regime, corresponding to exchange with minor conformations on the order of a few percent. Surprisingly, solution NMR and SAXS data on a larger Abl construct comprising the SH3-SH2-KD domains of the regulatory core show unequivocally that the core is in the assembled (autoinhibited) state in its apo form, but disassembles when the inhibitors imatinib or nilotinib bind (Figure 1b) . 7 
RESULTS AND DISCUSSION
The active and inactive A-loop conformations induced by type I and II inhibitors correlate strictly with the assembled and disassembled state of the regulatory core To carry out a comprehensive study of the assembled and disassembled state of the SH3- We then asked whether PC1 correlates also to the A-loop conformation observed in various Abl complex structures. For this, the PDB was searched for entries with ≥ 90 % sequence similarity to the human Abl imatinib complex (2HYY) yielding a total of 51 structures (Supplementary Table 1 A mechanical model of allosteric effects controlling core assembly All observations on the allosteric effects of ATP site and myristoyl binding pocket ligands onto the assembly state of the core can be rationalized by a simple mechanical model ( Figure   3d ). In complexes of KD-only constructs with type II inhibitors the A-loop is pushed to the inactive conformation resulting in the rotation of the KD-N lobe towards the SH3 interface. In such constructs and in the absence of a suitable ligand in the myristoyl pocket, the C-terminal αI' helix of the KD-C lobe is flexible in solution as evident from NMR. 7, 34 In KD crystal structures without myristoyl binding site ligands, this helix adopts a straight conformation, which would clash with the SH2 domain in the assembled core. 5 We assume that albeit being flexible, helix αI' also samples this clashing conformation to some extent in solution. The full Abl core in its apo form is assembled in solution and its KD-N lobe shows micro-to millisecond mobility as evidenced by NMR line broadening. 7 In this state, the motion of αI' must be restricted due to the steric hindrance by the SH2 domain. This results in a reduction of entropy and a higher free energy, i.e. a force directed, but not yet sufficient, to open the core. For the clinical response to kinase inhibitors, besides molecular binding mode and its influence on the assembly state of the Abl core domains that are described here, additional mechanisms will certainly also contribute. These include the presence of Bcr-Abl tetramers in cells due to the N-terminal coiled-coil oligomerization domain 35 and a yet to be explored (Figure 3e) . It has been noted early on that in this conformation nucleotide entry or release must be strongly inhibited and that the opening of the catalytic cleft by a rotation of the N-lobe is the likely prerequisite for ADP release, which is the rate limiting step in many kinases. 39 We can estimate from the solved ternary complexes that, in order to allow nucleotide binding or release, the P-loop must move by at least one atom layer (Figure 3e ) in the direction of the SH3 domain of the fully assembled core. This movement will be very similar in size and direction as the one observed for the change between the active (type I inhibitor) and inactive (type II inhibitor) A-loop structures, e.g. a movement of P-loop residue V275 by 1.5 Å (van der Waals radius of oxygen)
will induce a 7˚-rotation of the entire N-lobe around the hinge (G340) in the direction of the SH3 interface. This motion is possible in the disassembled regulatory core, but must be strongly hindered in the assembled core by the presence of the SH3 domain thereby reducing the speed of ATP binding and ADP release and hindering the catalytic reaction (Figure 3f) . The tight connection between A-/P-loop and core assembly state also provides highresolution insight into the autoinhibition mechanism, since it implies that the SH3 domain in the assembled state severely hinders the P-loop motion, which would be required for nucleotide binding and release. An identical inhibition mechanism is expected for all nonreceptor tyrosine kinases with an SH3-SH2-KD core.
CONCLUSION
The autoinhibition by the assembled core constitutes only one of Abl's regulation mechanisms. Interactions with cellular partners and phosphorylation provide further layers of regulation. In particular upon Abl activation, the activation loop gets phosphorylated at Y412, 40, 41 which stabilizes the open, active A-loop conformation. 
EXPERIMENTAL SECTION
Ligands. All ligands were purchased from commercial suppliers and used without further purification (Supplementary Table 2 ). Bosutinib was confirmed to be the correct isomer by solution NMR.
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Protein expression and purification. The 83-534 fragment of Abl (Abl 1b numbering) was expressed in 15 N-labeled form in E. coli strain BL21(DE3) and purified as described earlier The 138-536 fragment of SH2-KD Abl (Abl 1b numbering) construct was expressed in E.
coli strain BL21(DE3) and purified using the published protocol. Fractions containing LPP were pooled and adjusted to a final concentration of 500 mM NaCl. 45 and analyzed with SPARKY. 46 The principal component analysis of chemical shift variations was performed using MATLAB (Mathworks).
Analysis of PDB structures. PDB structures were analyzed and displayed using the PyMOL Molecular Graphics System (Schrodinger, LLC)
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